Literature DB >> 27714642

Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.

Ana Lucrecia Marcano1, José Luis Ferreiro2.   

Abstract

Dual therapy with a P2Y12 receptor antagonist in addition to aspirin is the antiplatelet treatment of choice in patients with acute coronary syndromes or undergoing percutaneous coronary intervention (PCI). However, available oral P2Y12 antagonists have several limitations, mostly due to their pharmacological profile, which can affect outcomes in certain clinical settings. Cangrelor is an intravenous, direct-acting, potent P2Y12 inhibitor with rapid onset and offset of action, which has been recently approved for clinical use in patients undergoing PCI. In clinical trials, cangrelor has demonstrated greater efficacy than clopidogrel with a favorable safety profile among PCI patients not receiving pretreatment with oral P2Y12 antagonists. However, its definitive role in contemporary practice is yet to be determined. This review aims to provide a comprehensive overview of the current status of knowledge on cangrelor, focusing on its pharmacological properties, clinical development, and the potential applications of this newly available agent.

Entities:  

Keywords:  Acute coronary syndrome; Antiplatelet therapy; Cangrelor; Percutaneous coronary intervention

Mesh：

Substances：

Year:  2016        PMID： 27714642     DOI： 10.1007/s11883-016-0617-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  60 in total

1.  Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

Authors:  Gilles Montalescot; Leonardo Bolognese; Dariusz Dudek; Patrick Goldstein; Christian Hamm; Jean-Francois Tanguay; Jurrien M ten Berg; Debra L Miller; Timothy M Costigan; Jochen Goedicke; Johanne Silvain; Paolo Angioli; Jacek Legutko; Margit Niethammer; Zuzana Motovska; Joseph A Jakubowski; Guillaume Cayla; Luigi Oltrona Visconti; Eric Vicaut; Petr Widimsky
Journal:  N Engl J Med       Date:  2013-09-01       Impact factor: 91.245

Review 2.  Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery.

Authors:  S Savonitto; M Caracciolo; M Cattaneo; S DE Servi
Journal:  J Thromb Haemost       Date:  2011-11       Impact factor: 5.824

3.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard R Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Jeroen J Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasche; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; Jose-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Joao Morais; Carlos Aguiar; Wael Almahmeed; David O Arnar; Fabio Barili; Kenneth D Bloch; Ann F Bolger; Hans Erik Botker; Biykem Bozkurt; Raffaele Bugiardini; Christopher Cannon; James de Lemos; Franz R Eberli; Edgardo Escobar; Mark Hlatky; Stefan James; Karl B Kern; David J Moliterno; Christian Mueller; Aleksandar N Neskovic; Burkert Mathias Pieske; Steven P Schulman; Robert F Storey; Kathryn A Taubert; Pascal Vranckx; Daniel R Wagner
Journal:  J Am Coll Cardiol       Date:  2012-09-05       Impact factor: 24.094

4.  Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.

Authors:  Dominick J Angiolillo; Michael S Firstenberg; Matthew J Price; Pradyumna E Tummala; Martin Hutyra; Ian J Welsby; Michele D Voeltz; Harish Chandna; Chandrashekhar Ramaiah; Miroslav Brtko; Louis Cannon; Cornelius Dyke; Tiepu Liu; Gilles Montalescot; Steven V Manoukian; Jayne Prats; Eric J Topol
Journal:  JAMA       Date:  2012-01-18       Impact factor: 56.272

5.  Long-term use of ticagrelor in patients with prior myocardial infarction.

Authors:  Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2015-03-14       Impact factor: 91.245

Review 6.  Potential role of endogenous adenosine in ticagrelor-induced dyspnea.

Authors:  Yuly G Belchikov; Seth J Koenig; Elissa M Dipasquale
Journal:  Pharmacotherapy       Date:  2013-05-26       Impact factor: 4.705

Review 7.  Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Authors:  Anne Bellemain-Appaix; Stephen A O'Connor; Johanne Silvain; Michel Cucherat; Farzin Beygui; Olivier Barthélémy; Jean-Philippe Collet; Laurent Jacq; François Bernasconi; Gilles Montalescot
Journal:  JAMA       Date:  2012-12-19       Impact factor: 56.272

Review 8.  Cangrelor: a review on its mechanism of action and clinical development.

Authors:  José Luis Ferreiro; Masafumi Ueno; Dominick J Angiolillo
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-10

Review 9.  Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.

Authors:  David J Schneider
Journal:  Coron Artery Dis       Date:  2016-01       Impact factor: 1.439

10.  Intravenous platelet blockade with cangrelor during PCI.

Authors:  Deepak L Bhatt; A Michael Lincoff; C Michael Gibson; Gregg W Stone; Steven McNulty; Gilles Montalescot; Neal S Kleiman; Shaun G Goodman; Harvey D White; Kenneth W Mahaffey; Charles V Pollack; Steven V Manoukian; Petr Widimsky; Derek P Chew; Fernando Cura; Ivan Manukov; Frantisek Tousek; M Zubair Jafar; Jaspal Arneja; Simona Skerjanec; Robert A Harrington
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245
View more
  1 in total

Review 1.  Antiplatelet Therapy in Acute Coronary Syndrome.

Authors:  Kerry Layne; Albert Ferro
Journal:  Eur Cardiol       Date:  2017-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.